These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31372024)

  • 41. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.
    Bouza C; Angeles M; Muñoz A; Amate JM
    Addiction; 2004 Jul; 99(7):811-28. PubMed ID: 15200577
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacotherapy for alcohol dependence: status of current treatments.
    Franck J; Jayaram-Lindström N
    Curr Opin Neurobiol; 2013 Aug; 23(4):692-9. PubMed ID: 23810221
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Medical management of alcohol use disorders].
    Paille F
    Rev Prat; 2019 Oct; 69(8):909-916. PubMed ID: 32237660
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: interrupted time series evaluation of effectiveness.
    Harris AH; Bowe T; Hagedorn H; Nevedal A; Finlay AK; Gidwani R; Rosen C; Kay C; Christopher M
    Addict Sci Clin Pract; 2016 Sep; 11(1):15. PubMed ID: 27633982
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacotherapy for relapse prevention of alcohol use disorder in the Indian setting: A systematic review.
    Bharadwaj B; Selvakumar N; Kuppili PP
    Ind Psychiatry J; 2018; 27(2):163-171. PubMed ID: 31359967
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug-drug interactions in the treatment for alcohol use disorders: A comprehensive review.
    Guerzoni S; Pellesi L; Pini LA; Caputo F
    Pharmacol Res; 2018 Jul; 133():65-76. PubMed ID: 29719204
    [TBL] [Abstract][Full Text] [Related]  

  • 47. On the path towards personalized medicine: Implications of pharmacogenetic studies of alcohol use disorder medications.
    Nieto SJ; Grodin EN; Ray LA
    Expert Rev Precis Med Drug Dev; 2020; 5(1):43-54. PubMed ID: 34291172
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recent Developments in Pharmacotherapy of Alcoholism.
    Soyka M; Lieb M
    Pharmacopsychiatry; 2015 Jul; 48(4-5):123-35. PubMed ID: 25761458
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Practical outpatient pharmacotherapy for alcohol use disorder.
    Kim Y; Hack LM; Ahn ES; Kim J
    Drugs Context; 2018; 7():212308. PubMed ID: 29445407
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Opioid Receptor Antagonists in the Treatment of Alcoholism.
    Serecigni JG
    Adicciones; 2015 Sep; 27(3):214-30. PubMed ID: 26437315
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nalmefene in Alcohol Use Disorder Subjects with Psychiatric Comorbidity: A Naturalistic Study.
    Di Nicola M; De Filippis S; Martinotti G; De Risio L; Pettorruso M; De Persis S; Maremmani AGI; Maremmani I; di Giannantonio M; Janiri L
    Adv Ther; 2017 Jul; 34(7):1636-1649. PubMed ID: 28540656
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.
    Soyka M; Chick J
    Am J Addict; 2003; 12(s1):s69-s80. PubMed ID: 14972781
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disparities in pharmacotherapy for alcohol use disorder in the context of universal health care: a Swedish register study.
    Karriker-Jaffe KJ; Ji J; Sundquist J; Kendler KS; Sundquist K
    Addiction; 2017 Aug; 112(8):1386-1394. PubMed ID: 28406579
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Paradoxes of evidence in Russian addiction medicine.
    Mendelevich VD; Zalmunin KY
    Int J Risk Saf Med; 2015; 27 Suppl 1():S102-3. PubMed ID: 26639682
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence.
    Sinclair JM; Chambers SE; Shiles CJ; Baldwin DS
    Drug Saf; 2016 Jul; 39(7):627-45. PubMed ID: 27023898
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cognitive effects of labeled addictolytic medications.
    Pujol CN; Paasche C; Laprevote V; Trojak B; Vidailhet P; Bacon E; Lalanne L
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():306-332. PubMed ID: 28919445
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Naltrexone efficacy in treating alcohol-use disorder in individuals with comorbid psychosis: a systematic review.
    Sawicka M; Tracy DK
    Ther Adv Psychopharmacol; 2017 Sep; 7(8-9):211-224. PubMed ID: 28959434
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stevenson M; Pandor A; Stevens JW; Rawdin A; Rice P; Thompson J; Morgan MY
    Pharmacoeconomics; 2015 Aug; 33(8):833-47. PubMed ID: 25851485
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore.
    Goh ET; Morgan MY
    Aliment Pharmacol Ther; 2017 Apr; 45(7):865-882. PubMed ID: 28220511
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety of nalmefene for the treatment of alcohol use disorder: an update.
    López-Pelayo H; Zuluaga P; Caballeria E; Van den Brink W; Mann K; Gual A
    Expert Opin Drug Saf; 2020 Jan; 19(1):9-17. PubMed ID: 31868031
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.